Archive

Sensitivity of investment and valuation to drug price indices and market conditions

The empirical analysis of public sector investments and the health value created by the drugs selected for Medicare price negotiations provides a cost basis for the assessment of the maximum fair price.

The principal threat to economic stability currently is the overhang of debt, both private and public.

Increased hospital system consolidation in small Metropolitan Statistical Areas is adversely related to nurse wage growth.

Real Estate Investment Trusts (REITs) are considered “passive” investors and are exempt from corporate tax. But in reality, they play a very active role in reshaping whole industries, like healthcare.

US regulators can step in to ensure drug pricing both supports patient access and drug development

This paper considers the relationship between profits realized from higher insulin list prices, pharmaceutical innovation, and the financial structures of the three dominant insulin manufacturing companies, which set list prices.

As Covid-19 spreads globally in the first quarter of 2020, this paper finds that firms’ primary concerns relate to the collapse of demand, increased uncertainty, and disruption in supply chains

Private equity firms have become major players in the healthcare industry. How has this happened and what are the results?